Physician profile
Jeanne Knight
NPI 1174588875
$6,278.57
in general payments reported to CMS, 2019-2025
16 companies · $1,948 in 2025
The $1,948 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $375 · 2022: $1,408 · 2023: $1,610 · 2024: $938 · 2025: $1,948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,384 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,383.81 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,746.99 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Vanda Pharmaceuticals INC. | $1,406.82 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $723.93 | 2021-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $472.19 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $355.04 | 2022-2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $348.42 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $240.11 | 2023-2025 | Rexulti |
| Abbvie INC. | $196.91 | 2022-2025 | |
| Alkermes, INC. | $171.00 | 2022-2023 | Aristada, Aristada Initio |
| Luye Pharma (USA) Ltd. | $116.53 | 2025 | Erzofri Extended-Release |
| Ironshore Pharmaceuticals INC. | $116.39 | 2024 | |
| Corium, LLC | $114.91 | 2022 | |
| Idorsia Pharmaceuticals US INC | $99.33 | 2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $92.72 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $59.18 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $18.10 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeanne Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.